A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Epistemonikos ID: df426f0d6ed9d526c75317e3f85110c99f545fb1
First added on: Oct 28, 2025